Li Jian-Ri, Wang Shian-Shiang, Yang Cheng-Kuang, Chen Chuan-Su, Ho Hao-Chung, Chiu Kun-Yuan, Hung Chi-Feng, Cheng Chen-Li, Yang Chi-Rei, Chen Cheng-Che, Wang Shu-Chi, Lin Chia-Yen, Ou Yen-Chuan
Division of Urology, Department of Surgery, Taichung Veterans General HospitalTaichung, Taiwan; Institute of Medicine, Chung Shan Medical UniversityTaichung, Taiwan; Department of Medicine and Nursing, Hungkuang UniversityTaichung, Taiwan.
Division of Urology, Department of Surgery, Taichung Veterans General HospitalTaichung, Taiwan; Institute of Medicine, Chung Shan Medical UniversityTaichung, Taiwan; Department of Applied Chemistry, National Chi Nan UniversityNantou, Taiwan.
Front Pharmacol. 2017 Feb 13;8:55. doi: 10.3389/fphar.2017.00055. eCollection 2017.
We performed a chart review study in our castration-resistant prostate cancer (CRPC) patients who received Abiraterone acetate (AA) treatment after docetaxel and identified clinical markers which can predict treatment outcome. : From 2012 to 2016, 64 patients who received docetaxel after CRPC followed by AA treatment were included. Clinical parameters were recorded and analysis was performed to identify associations between pre-treatment variables and treatment outcome. : Thirty three patients (51.6%) achieved a decrease in PSA of 50%. The median PSA progression-free survival and overall survival in the total cohort of 64 patients were 6.6 and 24 months, respectively. Adverse events (AEs) in all grades developed in 35.9% (23/64) patients and mostly were grade 1 or 2. The most common AEs were gastric upset, hypokalemia and elevated liver function tests. Of the eight variables analyzed, first line androgen deprivation therapy (ADT) duration showed positive association to progression free survival (HR 0.98, 95% CI [0.96-0.99], = 0.012) and overall survival (HR 0.97, 95% CI [0.94-0.99], = 0.019). Pre-AA PSA and PSA progression ratio showed negative association only to progression free survival (HR 1.0, 95% CI [1.000-1.002], = 0.025, HR 1.01, 95% CI [1.00-1.01], < 0.001, respectively). : First line ADT duration was positively associated with AA treatment efficacy in progression free survival and overall survival. It can be used as a pre-treatment predictor.
我们对在多西他赛后接受醋酸阿比特龙（AA）治疗的去势抵抗性前列腺癌（CRPC）患者进行了一项病历回顾研究，并确定了可预测治疗结果的临床标志物。：2012年至2016年，纳入了64例CRPC后接受多西他赛治疗随后接受AA治疗的患者。记录临床参数并进行分析，以确定治疗前变量与治疗结果之间的关联。：33例患者（51.6%）实现了PSA降低50%。64例患者的总队列中，PSA无进展生存期和总生存期的中位数分别为6.6个月和24个月。35.9%（23/64）的患者发生了所有级别的不良事件（AE），大多数为1级或2级。最常见的AE是胃部不适、低钾血症和肝功能检查升高。在分析的八个变量中，一线雄激素剥夺治疗（ADT）持续时间与无进展生存期呈正相关（HR 0.98，95% CI [0.96 - 0.99]，P = 0.012）和总生存期呈正相关（HR 0.97，95% CI [0.94 - 0.99]，P = 0.019）。AA治疗前PSA和PSA进展率仅与无进展生存期呈负相关（HR 1.0，95% CI [1.000 - 1.002]，P = 0.025，HR 1.01，95% CI [1.00 - 1.01]，P < 0.001）。：一线ADT持续时间在无进展生存期和总生存期方面与AA治疗疗效呈正相关。它可作为治疗前预测指标。
